骨髓增生异常综合症-话题@MedSci

#骨髓增生异常综合症#

5篇内容 | 678人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198132, encodeId=102a21981320c, content=<a href='/topic/show?id=a8cfe80487f' target=_blank style='color:#2F92EE;'>#细胞遗传学#</a> <a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=骨髓增生异常综合征细胞遗传学分类, objectType=article, longId=821264, objectId=197a8212642f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221121/1669073014035_4754896.webp, objectUrl=/article/show_article.do?id=197a8212642f, replyNumber=0, likeNumber=5, createdTime=2024-04-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=197a8212642f, moduleTitle=骨髓增生异常综合征细胞遗传学分类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=197a8212642f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1615809, encodeId=e6511615809e7, content=<a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=34, createdTime=2021-01-06, rootId=0, userName=12498a1cm73暂无昵称, userId=f20719676220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615808, encodeId=3b6e16158080e, content=<a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, objectType=article, longId=204980, objectId=817f204980c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817f204980c0, replyNumber=0, likeNumber=41, createdTime=2020-12-31, rootId=0, userName=12498a1cm73暂无昵称, userId=f20719676220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817f204980c0, moduleTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=817f204980c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615807, encodeId=ee64161580ec6, content=<a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, objectType=article, longId=191464, objectId=43e019146416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43e019146416, replyNumber=0, likeNumber=32, createdTime=2020-04-06, rootId=0, userName=12498a1cm73暂无昵称, userId=f20719676220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43e019146416, moduleTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43e019146416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615806, encodeId=39441615806a8, content=<a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=Sci Transl Med：冷泉港实验室华人科学家发现改善骨髓增生异常综合症新疗法, objectType=article, longId=180639, objectId=9179180639cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9179180639cc, replyNumber=0, likeNumber=35, createdTime=2019-10-09, rootId=0, userName=12498a1cm73暂无昵称, userId=f20719676220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9179180639cc, moduleTitle=Sci Transl Med：冷泉港实验室华人科学家发现改善骨髓增生异常综合症新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9179180639cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615805, encodeId=76fd161580544, content=<a href='/topic/show?id=96421019666b' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合症#</a>, objectTitle=GSK启动eltrombopag骨髓增生异常综合症III期SUPPORT研究, objectType=article, longId=37292, objectId=978e3e292c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978e3e292c3, replyNumber=0, likeNumber=30, createdTime=2014-07-04, rootId=0, userName=12498a1cm73暂无昵称, userId=f20719676220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978e3e292c3, moduleTitle=GSK启动eltrombopag骨髓增生异常综合症III期SUPPORT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978e3e292c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

骨髓增生异常综合症

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#细胞遗传学# #骨髓增生异常综合症#

骨髓增生异常综合征细胞遗传学分类

2024-04-12发表于上海

12498a1cm73暂无昵称 (审核中...)

前往app查看评论内容

#骨髓增生异常综合症#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-01-06

12498a1cm73暂无昵称 (审核中...)

前往app查看评论内容

#骨髓增生异常综合症#

Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点

2020-12-31

12498a1cm73暂无昵称 (审核中...)

前往app查看评论内容

#骨髓增生异常综合症#

FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血

2020-04-06

12498a1cm73暂无昵称 (审核中...)

前往app查看评论内容

#骨髓增生异常综合症#

Sci Transl Med：冷泉港实验室华人科学家发现改善骨髓增生异常综合症新疗法

2019-10-09

12498a1cm73暂无昵称 (审核中...)

前往app查看评论内容

#骨髓增生异常综合症#

GSK启动eltrombopag骨髓增生异常综合症III期SUPPORT研究

2014-07-04

科室
- - 订阅+
  - 更多科室
工具
服务